FDA Approves Trabectedin for Sarcoma

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact ...

Trabectedin has been approved by the Federal Drug Administration (FDA) ... sarcoma, ovarian cancer, endometrial cancer. Citation: Gadducci A ...

Trabectedin improves disease control in patients with advanced soft ...

Trabectedin is approved in 77 countries in North America, Europe, South America and Asia under the trade name Yondelis for the treatment of ...

Janssen's Yondelis gets FDA approval to treat unresectable or ...

Janssen Biotech has received approval from the US Food and Drug Administration (FDA) for Yondelis (trabectedin) to treat patients with ...

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S.

0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) in a connective tissue cancer ...

SARCOMA | Page 3 - Targeted Oncology

The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.

FDA clears J&J's chemotherapy for certain soft tissue sarcomas

The U.S. Food and Drug Administration said it approved Johnson & Johnson's chemotherapy to treat specific soft-tissue sarcomas (STS) that ...

FDA approves Yondelis for certain types of sarcoma - Patient Daily

The U.S. Food and Drug Administration (FDA) siad Friday it has approved Yondelis (trabectedin), a chemotherapy, for the treatment of ...

U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for ...

"We are excited the FDA has granted Priority Review for YONDELIS, as it is an important step forward in making this therapy available to ...

Yondelis® Bests Standard Therapy in Liposarcoma and ...

The trial included 518 patients with metastatic soft-tissue sarcoma (cancer spread to distant sites in the body) who had received prior therapy ...

Trabectedin for advanced soft tissue sarcoma: Ten-year real-life ...

Background: Trabectedin is a marine - derived chemotherapy, which lately received FDA approval for use in anthracycline resistant advanced ...

Advances in Sarcoma: Focus on Clinical Trials - OHSU

Trabectedin / Liposarcoma & Leiomyosarcoma. FDA approved Oct 2015. Demetri 2015 JCO. Sea squirt. No difference in OS. Page 15. 15. FDA approved Jan 2016.

FDA Approves Options for Melanoma, Soft Tissue Sarcomas

The FDA has approved Imlygic (talimogene laherparepvec) for the treatment of melanoma lesions in both the skin and lymph nodes.1. Imlygic, a genetically ...

U S Fda Approves Yondelis Trabectedin For The Treatment Of ...

U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two ...

MP-RX-FP-148-24 - Medical Policy

The chart below includes dosing recommendations as per the. FDA-approved prescribing information. Drug. Recommended Dosing Schedule. Trabectedin (Yondelis®). - ...

Yondelis (trabectedin) dosing, indications, interactions ... - Medscape

Medscape - Soft tissue sarcoma dosing for Yondelis (trabectedin), frequency-based adverse effects, comprehensive interactions, contraindications, ...

Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)

Classification, incidence and management of sarcomas · Integration of the recently FDA-approved agents trabectedin and eribulin into the treatment algorithms for ...

YONDELIS-pi.pdf - Janssen

tissue sarcoma receiving YONDELIS were: Nervous system disorders ... Advise the patient to read the FDA-approved patient labeling (Patient Information).

First-Line Doxorubicin Plus Trabectedin Vs Alone Yielded Improved ...

FDA Clears HLA Typing Companion Diagnostic for Afami-cel in Sarcoma ... Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase.

The Role of Trabectedin in Soft Tissue Sarcoma - Frontiers

In 2015, trabectedin has been approved by the FDA based on the result of an open-label, randomized (2:1) phase III trial of trabectedin (n = 345) ...

New drug approved for soft-tissue cancer - Medical Xpress

(HealthDay)—The chemotherapy drug Yondelis (trabectedin) has been approved by the U.S. Food and Drug Administration to treat certain ...